Mark D. Plinio - 19 Jan 2022 Form 4 Insider Report for Evelo Biosciences, Inc.

Role
Chief Commercial Officer
Signature
/s/ Daniel S. Char, Attorney-in-Fact for Luca Scavo
Issuer symbol
EVLO on OTC
Transactions as of
19 Jan 2022
Net transactions value
$0
Form type
4
Filing time
21 Jan 2022, 15:58:36 UTC
Previous filing
16 Jun 2021
Next filing
01 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EVLO Stock Option (Right to Buy) Award $0 +60,000 $0.000000 60,000 19 Jan 2022 Common Stock 60,000 $5.05 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options will vest in forty-eight (48) substantially equal installments at the end of each monthly anniversary of the date of grant, subject to continued employment on such dates.